Next-Generation Psychedelics Gain Attention in Biotech Industry
Next-generation psychedelics are gaining attention in the biotech industry as companies like Seaport Therapeutics and Gilgamesh Pharmaceuticals secure significant venture funding for their innovative approaches. These new psychedelic drugs aim to revolutionize mental health treatments, offering potential solutions beyond traditional psychedelics like psilocybin and LSD. Despite challenges in clinical use, the growing interest in psychedelic research highlights the industry’s shift towards innovative treatment approaches for mental health conditions.
Emotional Awareness Therapy Shows Promise in Addressing Chronic Pain in Older Adults
New research suggests that emotional awareness and expression therapy (EAET) may be more effective in addressing chronic pain among older adults compared to cognitive behavioral therapy (CBT). A study conducted at UCLA found that older adults undergoing EAET experienced a 30% reduction in pain, with sustained relief six months post-treatment. EAET also showed benefits in addressing psychiatric conditions like anxiety, depression, and PTSD. This study underscores the importance of emotional therapy in managing chronic pain in older adults.
Study Shows Promise of MDMA-Assisted Therapy for PTSD
A recent study published in Nature Medicine has revealed promising results for individuals suffering from moderate to severe post-traumatic stress disorder (PTSD). The research, conducted as a double-blinded randomized clinical trial, found that combining the drug MDMA with psychotherapy can…